BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.22
-0.16 (-1.91%)
At close: Mar 13, 2026, 4:00 PM EDT
8.15
-0.07 (-0.85%)
After-hours: Mar 13, 2026, 7:38 PM EDT

BioCryst Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
874.84450.71331.41270.83157.17
Revenue Growth (YoY)
94.10%36.00%22.37%72.31%782.38%
Cost of Revenue
19.0812.274.486.417.23
Gross Profit
855.76438.44326.93264.42149.94
Selling, General & Admin
348.65266.35214.07159.37118.82
Research & Development
166.13174.64216.57253.3208.81
Other Operating Expenses
---0.190.04
Total Operating Expenses
514.77440.99430.64412.85327.66
Operating Income
340.99-2.54-103.71-148.44-177.72
Interest Income
10.6714.7515.785.130.06
Interest Expense
-78.87-98.52-108.24-99.09-59.29
Other Non-Operating Income (Expense)
-5.39-0.64-30.06-1.9855.14
Total Non-Operating Income (Expense)
-73.6-84.41-122.52-95.95-4.09
Pretax Income
267.39-86.95-226.23-244.38-181.81
Provision for Income Taxes
3.531.930.312.732.25
Net Income
263.86-88.88-226.54-247.12-184.06
Net Income to Common
263.86-88.88-226.54-247.12-184.06
Shares Outstanding (Basic)
210207192186179
Shares Outstanding (Diluted)
219207192186179
Shares Change (YoY)
5.75%7.54%3.38%3.79%7.08%
EPS (Basic)
1.26-0.43-1.18-1.33-1.03
EPS (Diluted)
1.21-0.43-1.18-1.33-1.03
Free Cash Flow
344.9-53.14-97.31-163.1-144.54
Free Cash Flow Per Share
1.58-0.26-0.51-0.88-0.81
Gross Margin
97.82%97.28%98.65%97.63%95.40%
Operating Margin
38.98%-0.56%-31.29%-54.81%-113.08%
Profit Margin
30.16%-19.72%-68.36%-91.24%-117.11%
FCF Margin
39.42%-11.79%-29.36%-60.22%-91.97%
EBITDA
342.38-1.3-102.05-147-176.94
EBITDA Margin
39.14%-0.29%-30.79%-54.28%-112.58%
EBIT
340.99-2.54-103.71-148.44-177.72
EBIT Margin
38.98%-0.56%-31.29%-54.81%-113.08%
Effective Tax Rate
1.32%-2.22%-0.14%-1.12%-1.24%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q